You are here

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

Last updated on February 17, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Huntsville, Alabama, 35801 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A diagnosis of RA based upon the American college of Rheumatology 1987 revised
criteria

- Active disease at Screening

- Stable dose of methotrexate between 10-25 mg/week oral or parenteral

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- A diagnosis of any other inflammatory or secondary, noninflammatory arthritis that, in
the opinion of the Investigator, would interfere with disease activity assessments

- A history of hypersensitivity or allergic type reactions to cyclooxygenase inhibitors,
opiates, aspirin or sulfonamides

NCT00424294
Pfizer
Terminated
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now